---
title: "Infliximab use among Crohn's disease patients. | Sutter Health"
description: "In a community-based setting infliximab use has steadily increased. Need to determine why a large number of patients discontinued their treatment."
url: "https://www.sutterhealth.org/research/publications/infliximab-use-among-crohns-disease-patients-1055312672"
---

1.  [Home](https://www.sutterhealth.org/) /
2.  [Research](https://www.sutterhealth.org/research) /
3.  [Research publications](https://www.sutterhealth.org/research/publications) /
4.  Infliximab use among Crohn's disease patients.

# Patterns of infliximab use among Crohn's disease patients in a community setting.

Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, & Herrinton LJ.

_Inflamm Bowel Dis. 14(9):1265-72. doi: 10.1002/ibd.20483._

2008-09-01

## Abstract

BACKGROUND: Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members.

METHODS: The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis.

RESULTS: Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P < 0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio \[OR\] = 1.52 with 95% confidence interval \[CI\] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab.

CONCLUSIONS: In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.

[PubMed abstract](https://www.ncbi.nlm.nih.gov/pubmed/18452199/)

## Research topics

-   [Crohn's Disease](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Crohn%27s+Disease%5C%22%22)
-   [Medical Informatics](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Medical+Informatics%5C%22%22)
-   [Pharmacoepidemiology](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Pharmacoepidemiology%5C%22%22)

## Related publications

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

-   Publication
    
    ### [Estimating generic drug use with electronic health records data from a health care delivery system: implications for quality improvement and research.](https://www.sutterhealth.org/research/publications/estimate-generic-drug-use-ehr-qi-1055312512)
    
    Nimbal V, Segal JB, Romanelli RJ.
    
    J Manag Care Spec Pharm. 22(10):1143-7. doi: 10.18553/jmcp.2016.22.10.1143.
    
    2016 Oct 01
    
-   Publication
    
    ### [Statin dosing instructions, medication adherence, and low-density lipoprotein cholesterol: a cohort study of incident statin users.](https://www.sutterhealth.org/research/publications/cohort-study-of-incident-statin-users-1055312767)
    
    Marcum ZA, Huang HC, Romanelli RJ.
    
    J Gen Intern Med. doi: 10.1007/s11606-019-05180-7. \[Epub ahead of print\]
    
    2019 Jul 31
    
-   Publication
    
    ### [Synergistic drug combinations from electronic health records and gene expression.](https://www.sutterhealth.org/research/publications/synergistic-drug-combos-ehr-gene-expression-1055312518)
    
    Low YS, Daugherty AC, Schroeder EA, Chen W, Seto T, Weber S, Lim M, Hastie T, Mathur M, Desai M, Farrington C, Radin AA, Sirota M, Kenkare P, Thompson CA, Yu PP, Gomez SL, Sledge GW Jr, Kurian AW, Shah NH.
    
    J Am Med Inform Assoc. pii: ocw161. doi: 10.1093/jamia/ocw161. \[Epub ahead of print\]
    
    2016 Dec 09
    
-   Publication
    
    ### [User characteristics and out-of-pocket expenditures for progestin-only versus combined oral contraceptives.](https://www.sutterhealth.org/research/publications/user-chars-expenditures-oral-contraceptives-1055312830)
    
    Liang SY, Grossman D, Phillips KA.
    
    Contraception. 86(6):666-72. doi: 10.1016/j.contraception.2012.05.018. Epub 2012 Jul 6.
    
    2012 Dec 01
    
-   Publication
    
    ### [Inability of primary care providers to predict medication fulfillment of new prescriptions.](https://www.sutterhealth.org/research/publications/pcps-unable-to-predict-medication-fulfillment-1055312720)
    
    Wright EA, VanLoan RP, Sundaresan AS, Jones JB, Xie J, Fischer MA.
    
    J Patient Cent Res Rev. 2(2):129.
    
    2015 Apr 30
    

[View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication)

```json
{"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]}
```

```json
{"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/infliximab-use-among-crohns-disease-patients-1055312672#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Infliximab use among Crohn's disease patients."}]}
```

```json
{"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/infliximab-use-among-crohns-disease-patients-1055312672#medicalscholarlyarticle","name":"Patterns of infliximab use among Crohn's disease patients in a community setting.","headline":"Infliximab use among Crohn's disease patients.","abstract":"BACKGROUND: Information on infliximab use in a community setting is important to understand patterns of medication use and to anticipate and plan for costs associated with the drug. We sought to understand predictors of initiation and discontinuation of infliximab in the community-based setting of Kaiser Permanente, Northern California, which provides integrated care to its members. METHODS: The cohort study was set during 1998-2006. Predictors of initiation were assessed among 494 Crohn's disease (CD) patients who initiated infliximab and 2470 CD patients who did not initiate infliximab (controls). Data were obtained through linkage of computerized clinical information and were analyzed using logistic regression and Cox survival analysis. RESULTS: Infliximab infusions have increased rapidly since 2001, with no evidence of leveling off. Initiators were appreciably younger than controls (P \u003c 0.001), but were similar to controls with respect to sex and race/ethnicity. The presence of at least 1 comorbidity was related to a modest increase in the risk of initiating (compared with none: 1 comorbidity, odds ratio [OR] = 1.52 with 95% confidence interval [CI] 1.16-2.00; 2 comorbidities, OR = 1.38 with CI 0.89-2.13). By 3 years after initiating, only 20% of patients remained on infliximab. CONCLUSIONS: In a community-based setting infliximab use has steadily increased. Age and comorbidity are associated with initiation, but sex and race/ethnicity are not. More information is needed to determine why, in this community-based setting, a large number of patients on infliximab discontinued their treatment.","description":"In a community-based setting infliximab use has steadily increased. Need to determine why a large number of patients discontinued their treatment.","keywords":["Crohn's Disease","Medical Informatics","Pharmacoepidemiology"],"datePublished":"2008-09-01","url":"https://www.sutterhealth.org/research/publications/infliximab-use-among-crohns-disease-patients-1055312672","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"18452199"},{"@type":"PropertyValue","propertyID":"DOI","value":"10.1002/ibd.20483"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/18452199/","https://doi.org/10.1002/ibd.20483"],"isPartOf":{"@type":"Periodical","name":"Inflamm Bowel Dis"},"author":[{"@type":"Person","name":"Pressman AR"},{"@type":"Person","name":"Hutfless S"},{"@type":"Person","name":"Velayos F"},{"@type":"Person","name":"Fireman B"},{"@type":"Person","name":"Lewis JD"},{"@type":"Person","name":"Allison J"},{"@type":"Person","name":"Abramson O"},{"@type":"Person","name":"Herrinton LJ"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Crohn's Disease","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Crohn%27s+Disease%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Medical Informatics","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Medical+Informatics%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Pharmacoepidemiology","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Pharmacoepidemiology%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/infliximab-use-among-crohns-disease-patients-1055312672","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/infliximab-use-among-crohns-disease-patients-1055312672#breadcrumblist"}}}
```
